Molecular epidemiology of Clostridium difficile strains from nosocomial-acquired infections

[1]  Hyo Youl Kim,et al.  Epidemiology of Clostridium difficile infections in a tertiary-care hospital in Korea. , 2013, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[2]  N. Petrosillo,et al.  Clostridium difficile infection in Italian urban hospitals: data from 2006 through 2011 , 2013, BMC Infectious Diseases.

[3]  G. Kahlmeter,et al.  Antimicrobial susceptibility testing of Clostridium difficile using EUCAST epidemiological cut-off values and disk diffusion correlates. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[4]  C. Farina,et al.  Laboratory diagnosis of Clostridium difficile associated diarrhoea and molecular characterization of clinical isolates. , 2012, The new microbiologica.

[5]  H. Goossens,et al.  European Surveillance of Antimicrobial Consumption (ESAC): outpatient penicillin use in Europe (1997-2009). , 2011, The Journal of antimicrobial chemotherapy.

[6]  A. Le Monnier,et al.  Prevalence and diversity of Clostridium difficile strains in infants. , 2011, Journal of medical microbiology.

[7]  T. Pasanen,et al.  Comparison of repetitive extragenic palindromic sequence-based PCR with PCR ribotyping and pulsed-field gel electrophoresis in studying the clonality of Clostridium difficile. , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[8]  Shyr‐Yi Lin,et al.  Antimicrobial Susceptibilities and Molecular Epidemiology of Clinical Isolates of Clostridium difficile in Taiwan , 2011, Antimicrobial Agents and Chemotherapy.

[9]  N. Khardori.  Clostridium difficile infection in Europe: a hospital-based survey , 2011 .

[10]  Geert Molenberghs,et al.  European Surveillance of Antimicrobial Consumption (ESAC): outpatient quinolone use in Europe (1997-2009). , 2011, The Journal of antimicrobial chemotherapy.

[11]  D. Gerding,et al.  Human Hypervirulent Clostridium difficile Strains Exhibit Increased Sporulation as Well as Robust Toxin Production , 2010, Journal of bacteriology.

[12]  M. P. Bauer,et al.  The Changing Epidemiology of Clostridium difficile Infections , 2010, Clinical Microbiology Reviews.

[13]  P. Mastrantonio,et al.  Clostridium difficile Isolates Resistant to Fluoroquinolones in Italy: Emergence of PCR Ribotype 018 , 2010, Journal of Clinical Microbiology.

[14]  C. Wiedermann,et al.  Nosocomial diarrhoea in adult medical patients: the role of Clostridium difficile in a North Italian acute care teaching hospital. , 2009, Journal of preventive medicine and hygiene.

[15]  D. Gerding,et al.  Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. , 2009, Gastroenterology.

[16]  C. Kelly,et al.  Clostridium difficile--more difficult than ever. , 2008, The New England journal of medicine.

[17]  B. Wren,et al.  Comparative analysis of BI/NAP1/027 hypervirulent strains reveals novel toxin B-encoding gene (tcdB) sequences. , 2008, Journal of medical microbiology.

[18]  Carlene A. Muto,et al.  Antimicrobial-associated risk factors for Clostridium difficile infection. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  C. Woods,et al.  Comparison of Seven Techniques for Typing International Epidemic Strains of Clostridium difficile: Restriction Endonuclease Analysis, Pulsed-Field Gel Electrophoresis, PCR-Ribotyping, Multilocus Sequence Typing, Multilocus Variable-Number Tandem-Repeat Analysis, Amplified Fragment Length Polymorphis , 2007, Journal of Clinical Microbiology.

[20]  A. Collignon,et al.  Évaluation de l'antibiogramme par diffusion en milieu gélosé pour le dépistage de souches de Clostridium difficile de sensibilité diminuée aux antibiotiques , 2007 .

[21]  M. Delmée,et al.  Prospective study of Clostridium difficile infections in Europe with phenotypic and genotypic characterisation of the isolates. , 2007, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[22]  L. Mascola,et al.  Increase in Clostridium difficile–related Mortality Rates, United States, 1999–2004 , 2007, Emerging infectious diseases.

[23]  J. Hughes,et al.  The challenges posed by reemerging Clostridium difficile infection. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  M. Nicolas-Chanoine,et al.  [Interest of the disk diffusion method for screening Clostridium difficile isolates with decreased susceptibility to antibiotics]. , 2007, Pathologie et biologie.

[25]  Herman Goossens,et al.  European Surveillance of Antimicrobial Consumption (ESAC): outpatient antibiotic use in Europe. , 2011, The Journal of antimicrobial chemotherapy.

[26]  Herman Goossens,et al.  European Surveillance of Antimicrobial Consumption (ESAC): outpatient quinolone use in Europe. , 2006, The Journal of antimicrobial chemotherapy.

[27]  T. Åkerlund,et al.  Antimicrobial Susceptibility Pattern of Clostridium difficile and Its Relation to PCR Ribotypes in a Swedish University Hospital , 2006, Antimicrobial Agents and Chemotherapy.

[28]  M. Owings,et al.  Clostridium difficile Infection in Patients Discharged from US Short-stay Hospitals, 1996–2003 , 2006, Emerging Infectious Diseases.

[29]  T. Åkerlund,et al.  Correlation of Disease Severity with Fecal Toxin Levels in Patients with Clostridium difficile-Associated Diarrhea and Distribution of PCR Ribotypes and Toxin Yields In Vitro of Corresponding Isolates , 2006, Journal of Clinical Microbiology.

[30]  Stuart Johnson,et al.  An epidemic, toxin gene-variant strain of Clostridium difficile. , 2005, The New England journal of medicine.

[31]  T. Peláez,et al.  In Vitro Activity of Ramoplanin against Clostridium difficile, Including Strains with Reduced Susceptibility to Vancomycin or with Resistance to Metronidazole , 2005, Antimicrobial Agents and Chemotherapy.

[32]  A. Rodloff,et al.  Prevalence and characteristics of bacteria and host factors in an outbreak situation of antibiotic-associated diarrhoea. , 2005, Journal of medical microbiology.

[33]  Louis Valiquette,et al.  Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity , 2004, Canadian Medical Association Journal.

[34]  S. Poutanen,et al.  Clostridium difficile-associated diarrhea in adults , 2004, Canadian Medical Association Journal.

[35]  C. Klaassen,et al.  Molecular Fingerprinting of Clostridium difficile Isolates: Pulsed-Field Gel Electrophoresis versus Amplified Fragment Length Polymorphism , 2002, Journal of Clinical Microbiology.

[36]  R. Chiprut,et al.  [Clostridium difficile infection]. , 2002, Gaceta medica de Mexico.

[37]  M. Wilcox,et al.  Reduced susceptibility of Clostridium difficile to metronidazole. , 2001, The Journal of antimicrobial chemotherapy.

[38]  M. Alfa,et al.  Characterization of a Toxin A-Negative, Toxin B-Positive Strain of Clostridium difficile Responsible for a Nosocomial Outbreak of Clostridium difficile-Associated Diarrhea , 2000, Journal of Clinical Microbiology.

[39]  P. Coudron,et al.  Hospital-wide Restriction of Clindamycin: Effect on the Incidence of Clostridium difficile-Associated Diarrhea and Cost , 1998, Annals of Internal Medicine.

[40]  D. Gerding,et al.  Decrease in Nosocomial Clostridium difficileAssociated Diarrhea by Restricting Clindamycin Use , 1994, Annals of Internal Medicine.